EU plans risk reduction steps for Servier, Amgen heart drug

November 7, 2014 12:55 PM

1 0

LONDON (Reuters) - Experts at the European Medicines Agency have recommended measures to reduce the risks associated with a drug from private French company Servier that helps lower the heart rate and which was licensed to U.S. group Amgen last year.

Ivabradine is not currently approved in the United States but it is sold in Europe for treating stable angina, or chest pain due to obstruction of heart arteries, and for heart failure, when the heart fails to pump blood effectively.

Also read: Novo’s New Insulin Reduces Risk of Low Blood Sugar, Study Shows

Read more

To category page

Loading...